Evidence map›Paper›PMID 41480285›Full record

ArticleFrontiers in artificial intelligence2025

Deep multimodal learning for domain-level cognitive decline prediction in Alzheimer's disease.

Fernando García-Gutiérrez, Jordi A Matias-Guiu, José L Ayala

Abstract read
In one paragraph

Article in Frontiers in artificial intelligence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Fernando García-GutiérrezDepartment of Computer Architecture and Automation, Universidad Complutense de Madrid, Madrid, Spain.
Jordi A Matias-GuiuDepartment of Neurology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain.
José L AyalaDepartment of Computer Architecture and Automation, Universidad Complutense de Madrid, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Alzheimer's disease (AD) is characterized by significant variability in clinical progression; however, few studies have focused on developing models to predict cognitive decline. Anticipating these trajectories is essential for patient management, care planning, and developing new treatments. This study explores the potential of artificial intelligence (AI) techniques to model neurocognitive trajectories from multimodal neuroimaging data and further investigates different data representation frameworks. Methods: Using information from 653 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI), we developed models to predict future clinical diagnoses and cognitive decline, both quantitatively (rate of decline) and qualitatively (presence or absence of decline). Input features included structural T1-weighted magnetic resonance imaging (MRI), [ Results: The modeling strategies demonstrated good predictive performance for future clinical diagnoses, consistent with previous studies (F1 = 0.779). Quantitative models explained approximately 29.4%-36.0% of the variance in cognitive decline. In the qualitative analysis, the models achieved AUC values above 0.83 when predicting cognitive deterioration in the memory, language, and executive function domains. Architecturally, CNN- and GNN-based models yielded the best performance, and the proposed pre-training strategy consistently improved predictive accuracy. Conclusions: This study demonstrates that AI techniques can capture patterns of cognitive decline by exploiting multimodal neuroimaging data. These findings contribute to the development of more precise phenotyping approaches for neurodegenerative patterns in AD.

Indexed as

Alzheimer's diseaseartificial intelligenceautomated pattern recognitionmachine learningneurodegenerative diseasesneuroimaging

Identifiers

PMID41480285
PMCPMC12753913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.